Roivant Sciences Ltd.

Clinical-stage biotech developing immunology and cardiopulmonary drug candidates

What Roivant Sciences does

Roivant develops experimental medicines, mostly for autoimmune and immune-mediated diseases, where the body's immune system attacks its own tissues. It is also developing an inhaled drug for high blood pressure in the lungs linked to lung scarring. It also has technology platforms for delivering drugs inside the body.

How Roivant Sciences makes money

As a clinical-stage company, Roivant spends money on drug research and clinical trials. It aims to earn revenue by commercializing its drug candidates once they are approved.

Products & services

• IMVT-1402 (anti-FcRn antibody)
• Batoclimab (anti-FcRn antibody)
• Brepocitinib (TYK2/JAK1 inhibitor)
• Mosliciguat (inhaled sGC activator)
• Lipid nanoparticle (LNP) delivery platform
• Ligand conjugate delivery platform